Arcane Bio · Private Allocation

DMC-3

Dermal Modulation Compound — Series 3

Developed for wound repair, validated for anti-aging, and quietly resolving skin conditions it was never designed for —

DMC-3 works because it doesn't treat symptoms. It reprograms the cells that cause them.

Allocation Window Closes April 27, 2026

Dispatched On or Before May 4, 2026

Strategic allocations are made by invitation on a per-production-run basis. The current window closes upon the date above, or upon fulfillment of remaining units — whichever comes first.

There are compounds that work well enough to create problems. Not for the people using them — for the systems that prefer those people remain in need of something else. DMC-3 has always lived in that category. Private distribution isn't a phase. It's a plan.

Before it had a name,
it had a reputation.

DMC-3 has circulated exclusively through private channels since inception.

To move freely — through private events, exclusive networks, and environments where a clinical compound would have drawn the wrong kind of attention — DMC-3 needed a face. That face was MEND™.

Same formulation. Same compound. Different name on the box. MEND™ was never a separate product — it was DMC-3 operating under a consumer identity, distributed quietly while the compound itself remained outside of retail classification.

Private distribution has included

Scientific Foundation

Originating from
clinical research.

Research conducted at UC Irvine's Sue & Bill Gross Islet Cell and Stem Cell Research Center — a facility that pioneered cellular communication methodologies, initially targeting autoimmune and neurodegenerative conditions.

The core technology, designed to influence cellular behavior without live-cell transplantation, has been adapted for topical delivery.

Research Institution UC Irvine Sue & Bill Gross Islet Cell and Stem Cell Research Center

Published In

01 Nature
02 The New England Journal of Medicine
03 ACS Nano

Real-world participants

12-month validation cohort · consistent improvement across multiple conditions

Tier-1 peer-reviewed journals

ACS Nano · Nature · New England Journal of Medicine

Hallmarks of aging addressed

Simultaneously — through coordinated biological signaling, not isolated actives

"Designed for conditions far more serious than aging — which is precisely why it works on aging."

System-Level Modulation

How it works.

DMC-3 operates at the signaling level — influencing how cells repair, regenerate, and maintain structural integrity over time.

Epigenetic Signaling

Introduces signaling environments that shift cells toward a functional, youthful state.

Autophagy Activation

Triggers the body's natural recycling system to clear damaged, inflammatory cells.

Sirtuin Pathway Support

Upregulates longevity pathways to promote DNA repair and stabilize cellular health.

Precision Delivery

Active biologicals delivered via precision biological carriers and proprietary gold nano cages.

Because it works at the cellular level, the condition is almost irrelevant. The biology responds the same way regardless of what label a dermatologist would put on it.

Observed Application Range

The following reflects outcomes observed across private distribution and the 50-person validation cohort. DMC-3 was not designed for any single condition — these are where it has been found to work.

Cosmetic & Anti-Aging

Fine Lines & WrinklesEpigenetic reprogramming of collagen-producing cells
Skin Texture & ToneStructural renewal through cellular turnover activation
HyperpigmentationMelanocyte signaling correction at the cellular level
Photodamage & UV ExposureDNA repair pathway activation and oxidative stress reduction
Loss of ElasticityFibroblast reactivation and structural protein resynthesis

Inflammatory Conditions

Acne & BreakoutsInflammatory cell clearance via autophagy activation
RosaceaVascular and inflammatory pathway modulation
Eczema & DermatitisImmune signaling correction and barrier repair
PsoriasisDysregulated cellular proliferation signaling reset
Seborrheic ConditionsSebaceous gland signaling normalization

Wound & Structural Repair

Post-Surgical RepairAccelerated tissue reconstruction and scar reduction
Chronic Wound ManagementNon-healing wound environments — the original clinical application
Diabetic Skin CompromiseRestoration of impaired cellular repair signaling
Burn & Trauma RecoveryAccelerated epithelial regeneration and pain signal modulation
Scarring & KeloidsFibrotic signaling correction during wound resolution

Extended Applications

Oncological AdjunctObserved in environments where conventional treatment was ongoing or had concluded. Outcomes in certain post-treatment cases have exceeded what the compound was designed to produce. Further documentation is ongoing.
Radiation DermatitisCellular repair support in radiation-compromised tissue
Autoimmune Skin PresentationsImmune signaling modulation across systemic skin conditions
Graft Site RecoveryAccelerated integration and reduced rejection signaling

Conditions reflect observed outcomes across private distribution and the 50-person validation cohort. DMC-3 / MEND™ is a cosmetic formulation. These are not medical claims.

Certain extended applications have produced outcomes beyond the scope of this document. Inquire directly.

Production Cycle & Allocation

Secure your allocation.

DMC-3 is manufactured in tightly controlled micro-batches, sterile filtered, and not scaled for mass retail. No additional units are scheduled following this allocation cycle. Reservations secured today will be dispatched on or before May 4, 2026.

Access Network BOA-NETWORK

Total Allocation 65 UNITS

Units Available 18 UNITS

Cycle Close APRIL 27, 2026

Clinical Access Rate $2,400.00

Founding Allocation $1,440.00

Select your allocation tier

Single Unit

$1,440

Clinical Access: $2,400

Secures your position in the current production schedule. Founding status extended on all future DMC-3 private releases.

Select

Three-Unit Allocation

3 units · $1,368 per unit

$4,104

Clinical Access: $7,200

Personal supply and a gifting reserve. Same founding status and priority production position.

Select

Strategic Allocation

10 units · $1,296 per unit

$12,960

Clinical Access: $24,000

Priority allocation on all subsequent DMC-3 production runs. Founding status across future Arcane Bio compound releases.

Select

For full-batch acquisitions, clinical deployment, or custom production for qualified groups, contact info@arcanebio.com.

What to know first.

What is DMC-3 and how does it relate to MEND™?

DMC-3 (Dermal Modulation Compound, Series 3) is the regenerative signaling compound at the core of Arcane Bio's platform, originally developed for clinical applications at UC Irvine. MEND™ is the product name under which DMC-3 is formulated and distributed in topical form — the only consumer expression of this technology currently accessible outside of direct clinical environments.

Is this publicly available?

No. DMC-3 has never been positioned for public retail and is not available through any commercial channel. Access is extended through private allocation windows to a limited network. This portal is not publicly indexed.

Is this a subscription?

No. One-time allocation purchase. No recurring billing, no subscription, no obligation beyond the initial reservation. Future access to subsequent DMC-3 production cycles is extended as a benefit of founding allocation status.

When does it ship?

Reservations secured today will be dispatched directly from our facility on or before May 4, 2026. Founding allocation holders receive priority fulfillment sequencing.

Does Arcane Bio make medical claims?

No. This portal provides information for private evaluation purposes only and does not constitute medical advice. DMC-3 / MEND™ is a cosmetic formulation. Those with medical concerns should consult a qualified professional.

✓

Message received.

Thank you. A member of the Arcane Bio team will respond to your inquiry within 48 hours.

DMC-3

Before it had a name,
it had a reputation.

Originating from
clinical research.

How it works.

Epigenetic Signaling

Autophagy Activation

Sirtuin Pathway Support

Precision Delivery

Secure your allocation.

What to know first.

Allocation Confirmed

Get in touch.

Message received.

DMC-3

Before it had a name,it had a reputation.

Originating fromclinical research.

How it works.

Epigenetic Signaling

Autophagy Activation

Sirtuin Pathway Support

Precision Delivery

Secure your allocation.

What to know first.

Get in touch.

Message received.

Before it had a name,
it had a reputation.

Originating from
clinical research.